Literature DB >> 9729614

An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones.

J N Kew1, J A Kemp.   

Abstract

1. The atypical NR2B subunit-selective NMDA receptor antagonist ifenprodil was originally believed to act as a competitive antagonist at the polyamine binding site of the NMDA receptor. However, a number of studies have suggested that ifenprodil might bind to a distinct site. 2. Using whole-cell voltage clamp recordings, we have studied the interaction of spermine with both ifenprodil and the related NR2B selective antagonist Ro 8-4304 at the NMDA receptor in rat cultured cortical neurones in the presence of saturating concentrations of glycine. 3. Ifenprodil and Ro 8-4304 inhibited steady-state currents evoked by 100 microM NMDA in the absence of spermine with IC50 values of 0.3 and 0.6 microM, respectively. In the presence of 1 and 3 mM spermine, IC50 values for ifenprodil were 1.4 and 1.8 microM and for Ro 8-4304 they were 3. 0 and 7.5 microM, respectively. 4. In the presence of spermine, the on-time constant of receptor blockade by both antagonists was significantly slower than control and the off-time constant of recovery from receptor blockade following removal of Ro 8-4304 was significantly faster. 5. Fast application of spermine during an NMDA steady-state current in the continuous presence of a subsaturating concentration of either antagonist resulted in a biphasic increase in the current, consistent with a fast increase upon spermine binding and a slow increase resultant from dissociation of antagonist due to spermine binding-induced allosteric reduction in receptor antagonist affinity. In agreement with this, at higher, saturating concentrations of antagonist, the slow increase in current amplitude was markedly reduced or absent. 6. These observations are consistent with a non-competitive, allosteric interaction between spermine and the antagonists, such that spermine binding to the NMDA receptor results in a reduction in receptor affinity for the antagonists and vice versa. 7. The effects of Mg2+ on the NMDA-evoked currents and its interaction with ifenprodil were similar to those of spermine, supporting the suggestion that Mg2+ might be the physiological ligand acting at the spermine site mediating glycine-independent stimulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9729614      PMCID: PMC2231188          DOI: 10.1111/j.1469-7793.1998.017bf.x

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  25 in total

1.  Is the discriminative stimulus produced by phencyclidine due to an interaction with N-methyl-D-aspartate receptors?

Authors:  A Jackson; D J Sanger
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro.

Authors:  G Fischer; V Mutel; G Trube; P Malherbe; J N Kew; E Mohacsi; M P Heitz; J A Kemp
Journal:  J Pharmacol Exp Ther       Date:  1997-12       Impact factor: 4.030

Review 3.  Developmental changes in NMDA receptor glycine affinity and ifenprodil sensitivity reveal three distinct populations of NMDA receptors in individual rat cortical neurons.

Authors:  J N Kew; J G Richards; V Mutel; J A Kemp
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

4.  Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia.

Authors:  B Gotti; D Duverger; J Bertin; C Carter; R Dupont; J Frost; B Gaudilliere; E T MacKenzie; J Rousseau; B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

5.  A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones.

Authors:  J N Kew; G Trube; J A Kemp
Journal:  J Physiol       Date:  1996-12-15       Impact factor: 5.182

6.  State-dependent NMDA receptor antagonism by Ro 8-4304, a novel NR2B selective, non-competitive, voltage-independent antagonist.

Authors:  J N Kew; G Trube; J A Kemp
Journal:  Br J Pharmacol       Date:  1998-02       Impact factor: 8.739

7.  Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines.

Authors:  I J Reynolds; R J Miller
Journal:  Mol Pharmacol       Date:  1989-11       Impact factor: 4.436

8.  An aspartate residue in the extracellular loop of the N-methyl-D-aspartate receptor controls sensitivity to spermine and protons.

Authors:  K Kashiwagi; J Fukuchi; J Chao; K Igarashi; K Williams
Journal:  Mol Pharmacol       Date:  1996-06       Impact factor: 4.436

9.  Effect of CP101,606, a novel NR2B subunit antagonist of the N-methyl-D-aspartate receptor, on the volume of ischemic brain damage off cytotoxic brain edema after middle cerebral artery occlusion in the feline brain.

Authors:  X Di; R Bullock; J Watson; P Fatouros; B Chenard; F White; F Corwin
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

10.  Ifenprodil and SL 82.0715 as cerebral antiischemic agents. III. Evidence for antagonistic effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex.

Authors:  C J Carter; K G Lloyd; B Zivkovic; B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1990-05       Impact factor: 4.030

View more
  18 in total

Review 1.  Control of assembly and function of glutamate receptors by the amino-terminal domain.

Authors:  Kasper B Hansen; Hiro Furukawa; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2010-07-21       Impact factor: 4.436

2.  The NMDA receptor intracellular C-terminal domains reciprocally interact with allosteric modulators.

Authors:  Kiran Sapkota; Kim Dore; Kang Tang; Mark Irvine; Guangyu Fang; Erica S Burnell; Roberto Malinow; David E Jane; Daniel T Monaghan
Journal:  Biochem Pharmacol       Date:  2018-11-29       Impact factor: 5.858

Review 3.  Ionotropic and metabotropic glutamate receptor structure and pharmacology.

Authors:  James N C Kew; John A Kemp
Journal:  Psychopharmacology (Berl)       Date:  2005-02-25       Impact factor: 4.530

4.  Allosteric interaction between zinc and glutamate binding domains on NR2A causes desensitization of NMDA receptors.

Authors:  Kevin Erreger; Stephen F Traynelis
Journal:  J Physiol       Date:  2005-09-15       Impact factor: 5.182

5.  The micromolar zinc-binding domain on the NMDA receptor subunit NR2B.

Authors:  Julie Rachline; Florent Perin-Dureau; Anne Le Goff; Jacques Neyton; Pierre Paoletti
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

6.  The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs.

Authors:  V Pedersen; W J Schmidt
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

7.  Leptin enhances NR2B-mediated N-methyl-D-aspartate responses via a mitogen-activated protein kinase-dependent process in cerebellar granule cells.

Authors:  A J Irving; L Wallace; D Durakoglugil; J Harvey
Journal:  Neuroscience       Date:  2006-01-18       Impact factor: 3.590

Review 8.  Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential.

Authors:  Laetitia Mony; James N C Kew; Martin J Gunthorpe; Pierre Paoletti
Journal:  Br J Pharmacol       Date:  2009-07-08       Impact factor: 8.739

9.  Studies on neuronal apoptosis in primary forebrain cultures: neuroprotective/anti-apoptotic action of NR2B NMDA antagonists.

Authors:  Jitendra R Dave; Anthony J Williams; John R Moffett; Michael L Koenig; Frank C Tortella
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

10.  GluN2D-Containing N-methyl-d-Aspartate Receptors Mediate Synaptic Transmission in Hippocampal Interneurons and Regulate Interneuron Activity.

Authors:  Riley E Perszyk; John O DiRaddo; Katie L Strong; Chian-Ming Low; Kevin K Ogden; Alpa Khatri; Geoffrey A Vargish; Kenneth A Pelkey; Ludovic Tricoire; Dennis C Liotta; Yoland Smith; Chris J McBain; Stephen F Traynelis
Journal:  Mol Pharmacol       Date:  2016-09-13       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.